References
- Brinton LT, Sloane HS, Kester M, et al (2015). Formation and role of exosomes in cancer. Cell Mol Life Sci, 72, 659-71. https://doi.org/10.1007/s00018-014-1764-3
- Chen L, Du J, Dai Q, et al (2014). Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking. Eur J Med Chem, 83, 294-306. https://doi.org/10.1016/j.ejmech.2014.06.037
- Chen Y, GouX, Ke X, et al (2012). Human tumor cells induce angiogenesis through positive feedback between CD147 and insulin-like growth factor-I. PLoS One, 7, 40965. https://doi.org/10.1371/journal.pone.0040965
- Chung AS, Kowanetz M, Wu X, et al (2012). Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol, 227, 404-16. https://doi.org/10.1002/path.4052
- Ding C, Zhang C, Zhang M, et al (2014). Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. Future Med Chem, 6, 1771-89. https://doi.org/10.4155/fmc.14.112
- Gammons MV, Lucas R, Dean R, et al (2014). Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer, 111, 477-85. https://doi.org/10.1038/bjc.2014.342
- Gatenby RA (2009). A change of strategy in the war on cancer. Nature, 459, 508-9. https://doi.org/10.1038/459508a
- Hensel JA, Flaig TW, Theodorescu D (2013). Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol, 10, 41-51.
- Hu H, Qiu Y, Guo M, et al (2015). Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models. Oncotarget, 6, 1079-89. https://doi.org/10.18632/oncotarget.2835
- Ji DB, Ye J, Jiang YM, et al (2009). Anti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice. BMC Complement Altern Med, 9, 20. https://doi.org/10.1186/1472-6882-9-20
- Johnson LM, Price DK, Figg WD (2013). Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment. Cancer Biol Ther, 14, 90-91. https://doi.org/10.4161/cbt.22636
- Kahlert C, Kalluri R (2013). Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl), 91, 431-7. https://doi.org/10.1007/s00109-013-1020-6
- Ke X, Fei F, Chen Y, et al (2012). Hypoxia upregulates CD147 through a combined effect of HIF-1alpha and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. Carcinogenesis, 33, 1598-607. https://doi.org/10.1093/carcin/bgs196
- Kidher E, Cheng Z, Jarral OA, et al (2014). In-vivo assessment of the morphology and hemodynamic functions of the BioValsalva composite valve-conduit graft using cardiac magnetic resonance imaging and computational modelling technology. J Cardiothorac Surg, 9, 193. https://doi.org/10.1186/s13019-014-0193-6
- Kwilas AR, Ardiani A, Donahue RN, et al (2014). Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med, 12, 294. https://doi.org/10.1186/s12967-014-0294-y
- Lavi O, Skinner J, Gottesman MM (2014). Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol, 8, 88. https://doi.org/10.1186/s12918-014-0088-0
- Mavrou A, Brakspear K, Hamdollah-Zadeh M, et al (2014). Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene.
- Melo SA, Sugimoto H, O'Connell JT, et al (2014). Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell, 26, 707-21. https://doi.org/10.1016/j.ccell.2014.09.005
- Pavelic J (2014). Editorial: combined cancer therapy. Curr Pharm Des, 20, 6511-2. https://doi.org/10.2174/1381612820666140826154834
- Prescott EL, Brimacombe CL, Hartley M, et al (2014). Human papillomavirus type 1 E1^E4 protein is a potent inhibitor of the serine-arginine (SR) protein kinase SRPK1 and inhibits phosphorylation of host SR proteins and of the viral transcription and replication regulator E2. J Virol, 88, 12599-611. https://doi.org/10.1128/JVI.02029-14
- Shand LK, Cowlishaw S, Brooker JE, et al (2014). Correlates of post-traumatic stress symptoms and growth in cancer patients: a systematic review and meta-analysis. Psychooncology, 24, 624-34.
- Sim BY, Lee YW, Kim H, et al (2014). Post-traumatic growth in stomach cancer survivors: Prevalence, correlates and relationship with health-related quality of life. Eur J Oncol Nurs.
- Sun Y, Campisi J, Higano C, et al (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med, 18, 1359-68. https://doi.org/10.1038/nm.2890
- Tang Y, Kesavan P, Nakada MT, et al (2004). Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res, 2, 73-80.
- Wojtowicz-Praga S (1997). Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother, 20, 165-177. https://doi.org/10.1097/00002371-199705000-00001
- Xia Q, Mao W (2014). Anti-tumor effects of traditional Chinese medicine give a promising perspective. J Cancer Res Ther, 10, 1-2.
- Yin Q, Shen J, Zhang Z, et al (2013). Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv Drug Deliv Rev, 65, 1699-715. https://doi.org/10.1016/j.addr.2013.04.011
- Zhai B, Sun XY (2013). Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol, 5, 345-52. https://doi.org/10.4254/wjh.v5.i7.345